

Department of Health and Human Services
National Institutes of Health
315th Meeting of the
National Heart, Lung, and Blood Advisory Council
June 9, 2026
Bethesda, MD

Open Session – 8:30 AM EDT **all times tentative*
Join videocast: <https://videocast.nih.gov/watch/460da6c5-4a1b-11f1-82c0-124f0a52e769>

Welcome Dr. David C. Goff, Acting Director, NHLBI
Administrative Announcements Dr. Charisee A. Lamar, Director, DERA, NHLBI
Report of the Director Dr. David C. Goff, Acting Director, NHLBI
Break
National Commission on Lymphatic Diseases Report Dr. Stanley Rockson, Ms. Stephanie Dreyer, and Ms. Alexa Ercolano
Retreat Recommendation Report Dr. Olveen Carrasquillo
NHLBI Concepts Dr. Charisee A. Lamar, Director, DERA, NHLBI
Public Comments
Adjournment

Closed Session – 12:00 PM EDT **all times tentative*

Welcome Dr. David C. Goff, Acting Director, NHLBI
Administrative Announcements Dr. Charisee A. Lamar, Director, DERA, NHLBI
Consideration of Grant Applications Division of Blood Diseases and Resources Blood Epidemiology and Clinical Therapeutics Branch Molecular Cellular and Systems Blood Science Branch Translational Blood Science and Resources Branch Dr. Julie Panepinto Dr. Arun Shet Dr. Allison Gillaspy Dr. Andrei Kindzelski Center for Translation Research and Implementation Science Health Inequities and Global Health Branch Implementation Science Branch Translation Research Branch Dr. George A. Mensah Dr. Maliha Ilias Dr. Cara Lewis Dr. George Mensah Division of Cardiovascular Sciences Advanced Technologies and Surgery Branch Dr. Vandana Sachdev Taneja* Dr. Kathleen Fenton RFA-HL-26-016: Catalyze: Enabling Technologies and Dr. Rahul Thakar

Transformative Platforms for HLBS Research (R33 – Clinical Trials Not Allowed)	
- RFA-HL-26-017: Catalyze: Product Definition for Small Molecules, Biologics and Combination Products - Target Identification and Validation and Preliminary Product/Lead Series Identification (R61/R33 Clinical Trial Not Allowed) - RFA-HL-26-018: Catalyze: Product Definition for Small Molecules, Biologics, and Combination Products - Preliminary Product/Lead Series Identification and Combination Product Prototype (R33 – Clinical Trial Not Allowed) - RFA-HL-26-019: Catalyze Product Definition – Medical Device Prototype design/testing and disease target identification and assay development (R61/R33 - Clinical Trial Not Allowed) - RFA-HL-26-020: Catalyze: Product Definition – Medical Device Prototype Optimization (R33 - Clinical Trial Not Allowed)	
Atherothrombosis and Coronary Artery Disease Branch	Dr. Jue Chen
RFA-HL-26-012: Stimulating Access to Research in Residency (StARR) (R38 Independent Clinical Trial Not Allowed)	Dr. Renee Wong
Clinical Applications and Prevention Branch	Dr. Charlotte Pratt
Epidemiology Branch	Dr. Yuling Hong
Heart Developmental and Structural Diseases Branch	Dr. Kristin Burns
Heart Failure and Arrhythmias Branch	Dr. Lisa Schwartz-Longacre
Vascular Biology and Hypertension Branch	Dr. Zorina Galis
Division of Lung Diseases	Dr. Marishka Brown*
Acute and Infectious Lung Diseases Branch	Dr. Guofei Zhou
Lung Development and Pediatric Diseases Branch	Dr. Marrah Lachowicz-Scroggins
RFA-HL-26-006: Viral INfections in the Young Lung- The VINYL Clinical Consortium (UG3/UH3 Clinical Trial Optional)	Dr. Marrah Lachowicz-Scroggins
RFA-HL-26-008: Viral INfections in the Young Lung- The VINYL Clinical Consortium- Data Analytics and Coordinating Center (DACC)(U24 Clinical Trial Optional)	Dr. Marrah Lachowicz-Scroggins
Obstructive Lung Diseases Branch	Dr. Lisa Postow
RFA-HL-25-011: Limited Competition: Small Grant Program for NHLBI K01/K08/K23/K25 Recipients (R03 Clinical Trial Optional)	Dr. Qing Lu
Restrictive and Vascular Lung Diseases Branch	Dr. John Sheridan
National Center on Sleep Disorders Research	Dr. Marishka Brown
*Acting Division Director	
Adjournment	

Future Meeting Dates

2026	2027
June 25, 2026 (Thursday – Virtual)	February 2 (Tuesday - Virtual)
August 18 (Tuesday – Virtual)	June 2 (Wednesday – w/BEE – In-person)

October 28 (Wednesday – In-person)

June 3 (Thursday – In-person)
August 17 (Tuesday – Virtual)
October 21 (Thursday – In-person)